Cutaneous castleman's disease responds to anti-interleukin-6 treatment

Molecular Cancer Therapeutics

Volumn 6, Issue 9, 2007, Pages 2386-2390

  Ahmed, Bilal ^a   Tschen, Jaime A ^b,f,g   Cohen, Philip R ^b,c   Zaki, Mohamed H ^h   Rady, Peter L ^d   Tyring, Stephen K ^e   Corringham, Robert E ^h   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d University of Texas Health Science Center at Houston   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g St Joseph Dermpath   (United States)

^h CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CTNO 328; HYDROXYCHLOROQUINE; INTERLEUKIN 6 ANTIBODY; MINOCYCLINE; PREDNISONE; RITUXIMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERANCE; ENZYME REPRESSION; FEMALE; HUMAN; HYPOTHESIS; MULTIPLE CANCER; PATHOLOGY; PLASMA CELL; PLASMACYTOSIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN-6; PLASMA CELLS; PROGNOSIS; SKIN NEOPLASMS;

EID: 34748822990     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0256     Document Type: Article

References (27)

1. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-9.
2. Klein WM, Rencic A, Munshi NC, Nousari CH. Multicentric plasma cell variant of Castleman's disease with cutaneous involvement. J Cutan Pathol 2004;31:448-52.
3. Kubota Y, Noto S, Takakuwa T, Tadokoro M, Mizoguchi M. Skin involvement in giant lymph node hyperplasia (Castleman's disease). J Am Acad Dermatol 1993;29:778-80.
4. Skelton HG, Smith KJ. Extranodal multicentric Castleman's disease with cutaneous involvement. Mod Pathol 1998;11:93-8.
5. Sleater J, Mullins D. Subcutaneous Castleman's disease of the wrist. Am J Dermatopathol 1995;17:174-8.
6. Amin HM, McLaughlin P, Rutherford CJ, Abruzzo LV, Jones D. Cutaneous and systemic plasmacytosis in a patient of Asian descent living in the United States. Am J Dermatopathol 2002;24:241-5.
7. Arico M, Bongiorno MR. Primary cutaneous plasmacytosis in a child. Is this a new entity? J Eur Acad Dermatol Venereol 2002;16:164-7.
8. Carey WP, Rico MJ, Nierodzik M, Sidhu G. Systemic plasmacytosis with cutaneous manifestations in a white man: successful therapy with cyclophosphamide/prednisone. J Am Acad Dermatol 1998;38:629-31.
9. Cerottini JP, Guillod J, Vion B, Panizzon RG. Cutaneous plasmacytosis: an unusual presentation sharing features with POEMS syndrome? Dermatology 2001;202:49-51.
10. Dubouloz M, Nydegger U, Cruchaud A, Harms M, Fabre J. [Cutaneous plasmacytosis and polyclonal cryo-immunoglobulinemia]. Schweiz Med Wochenschr 1978;108:34-9.
11. Hafner C, Hohenleutner U, Babilas P, Landthaler M, Vogt T. Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006;213:163-5.
12. Jayaraman AG, Cesca C, Kohler S. Cutaneous plasmacytosis: A report of five cases with immunohistochemical evaluation for HHV-8 expression. Am J Dermatopathol 2006;28:93-8.
13. Kaneda M, Kuroda K, Fujita M, Shinkai H. Successful treatment with topical PUVA of nodular cutaneous plasmacytosis associated with alopecia of the scalp. Clin Exp Dermatol 1996;21:360-4.
14. Kodama A, Tani M, Hori K, et al. Systemic and cutaneous plasmacytosis with multiple skin lesions and polyclonal hypergammaglobulinaemia: significant serum interleukin-6 levels. Br J Dermatol 1992;127:49-53.
15. Martin JM, Calduch L, Monteagudo C, et al. Cutaneous plasmacytosis associated with lung and anal carcinomas. J Eur Acad Dermatol Venereol 2006;20:428-31.
16. Miura H, Itami S, Yoshikawa K. Treatment of facial lesion of cutaneous plasmacytosis with tacrolimus ointment. J Am Acad Dermatol 2003;49:1195-6.
17. Shimizu S, Tanaka M, Shimizu H, Han-yaku H. Is cutaneous plasmacytosis a distinct clinical entity? J Am Acad Dermatol 1997;36:876-80.
18. Tada Y, Komine M, Suzuki S, et al. Plasmacytosis: systemic or cutaneous, are they distinct? Acta Derm Venereol 2000;80:233-5.
19. Tzung TY, Wu KH, Wu JC, Tseng HH. Primary cutaneous plasmacytosis successfully treated with topical photodynamic therapy. Acta Derm Venereol 2005;85:542-3.
20. Uhara H, Saida T, Ikegawa S, et al. Primary cutaneous plasmacytosis: report of three cases and review of the literature. Dermatology 1994;189:251-5.
21. Yamamoto T, Katayama I, Nishioka K. Increased plasma interleukin-6 in cutaneous plasmacytoma: the effect of intralesional steroid therapy. Br J Dermatol 1997;137:631-6.
22. Yamamoto T, Soejima K, Katayama I, Nishioka K. Intralesional steroid-therapy-induced reduction of plasma interleukin-6 and improvement of cutaneous plasmacytosis. Dermatology 1995;190:242-4.
23. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.
24. Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. Blood 1991;78:2923-30.
25. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother 2001;55:543-7.
26. F. van Rhee, Fayad L, Borghaei H, et al. CNTO 328, an interleukin (IL)-6 monoclonal antibody (mAB) - preliminary results of subjects with Castleman's disease from a phase 1 study in selected hematological malignances. Blood 2006;108:11:abstract 2728 (page 771a).
27. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.